ARIES Flu A/B & RSV Assay

ARIES Flu A/B & RSV is a sample-to-answer molecular test from Luminex (now part of DiaSorin) that detects influenza A, influenza B, and respiratory syncytial virus from a single nasopharyngeal swab in roughly two hours [1]. It runs as a closed cartridge on the ARIES instrument, which means a tech loads the sample, walks away, and gets a result - no manual PCR setup. The test slots into the mid-throughput hospital lab market against Cepheid's Xpert Flu/RSV XC and BioFire's respiratory panels [2][3].

Cleared by FDA under 510(k) K161220 in 2016, with a multicenter pediatric/adult clinical study supporting the submission [4]. This is a 510(k) clearance, not a PMA approval - meaning Luminex showed substantial equivalence to a predicate (a previously cleared device that the new test must demonstrate it works as well as) rather than running a de novo safety/effectiveness review. The product remains commercially available today through DiaSorin Molecular, which inherited the franchise when DiaSorin closed its acquisition of Luminex in July 2021 for $1.8 billion in cash (agreement announced April 1, 2021) [5]. Any CLIA-certified moderate-complexity lab can run it. Reimbursement falls under CPT 87631 (multiplex respiratory virus, 3-5 targets). The 2018 CMS Clinical Lab Fee Schedule (CLFS) priced this code around $142, and it has been subject to ongoing reductions under PAMA - the Protecting Access to Medicare Act of 2014, which benchmarks Medicare lab payment to private payer rates and triggered multi-year cuts to molecular pathology codes starting in 2018 [8]. The most recent CLFS revisions have brought the code closer to the $90-100 range, though laboratories should check the current-year CLFS file for the exact figure. Coverage is broad across commercial payers because multiplex respiratory PCR became standard of care during the 2017-2020 period and never went back.

The biology being measured is straightforward: viral RNA genomes from influenza A, influenza B, and RSV. The sample is a nasopharyngeal swab placed in viral transport medium. Inside the cartridge, the sample gets lysed (the viral envelope broken open), the RNA is captured on a magnetic bead, reverse-transcribed into DNA, and then amplified by real-time PCR using target-specific primers and fluorescent probes. Three colors come off the optical reader, one per target [4]. The technical differentiator versus competitors is not the chemistry - everyone is doing rRT-PCR - but the instrument architecture. ARIES holds twelve cartridges across two independent processing modules in random-access mode, meaning a lab can start a new sample whenever one arrives rather than batching, with throughput supporting up to roughly 48 samples per 8-hour shift [4][9]. Cepheid's GeneXpert offers a similar random-access workflow with a different cartridge format; BioFire's FilmArray is a single-sample-per-run system that covers far more pathogens (a 20+ target panel) but costs more per test. Published head-to-head comparisons against Xpert Flu/RSV showed positive and negative percent agreement above 95% for all three targets, with the residual discordances tracking to low-viral-load specimens where any PCR struggles [3].

The key evidence is the Juretschko multicenter study published in J Clin Microbiol in 2017, which tested 2,479 prospectively collected respiratory specimens from pediatric and adult patients across multiple US sites [4]. Per-target sensitivity in that study ranged approximately 97.7-98.1%, and specificity ranged 98.6% (RSV) to 99.6% (influenza A) to 99.8% (influenza B), measured against a composite reference standard - a combined gold standard built from two FDA-cleared comparator assays, used when no single definitive test exists - with disagreements resolved by discrepant analysis using bidirectional sequencing (when two tests disagree on a sample, sequencing the virus's genome settles the tie). This was the 510(k) submission package. Subsequent independent validations confirmed the performance: McMullen et al. ran ARIES head-to-head against Cepheid Xpert Flu/RSV XC on prospective patient samples and found the two assays clinically interchangeable [3]. Ling et al. compared ARIES to two other molecular platforms with similar agreement [2]. Banerjee et al. ran two separate comparative studies - one in pediatric specimens and one in adult specimens - across four to six sample-to-answer platforms, with ARIES holding its own against newer entrants [6][7]. The evidence here is analytical validity - does the test correctly identify the virus - not clinical utility in the rigorous sense (does using the test improve patient outcomes versus syndromic management). For respiratory viruses that's actually the right standard, because the clinical utility of rapid flu/RSV identification (oseltamivir for flu, isolation precautions, antibiotic stewardship) was established well before any specific molecular assay came to market.

This is a mature, commoditized segment. The respiratory molecular diagnostics market has three structural tiers: high-throughput multiplex panels (BioFire FilmArray, Luminex's own NxTAG, QIAstat-Dx) that detect 15-22 pathogens per run for $150-$200 reimbursement; mid-throughput targeted assays like ARIES, Xpert Flu/RSV, and cobas Liat that hit the three big winter pathogens for around $90-140; and point-of-care antigen tests that are cheaper and faster but miss cases. BioFire (owned by bioMérieux) dominates the syndromic panel tier. Cepheid (Danaher) is the dominant random-access cartridge platform globally because of its enormous TB and HIV installed base. ARIES is a credible but not leading player in the random-access space - DiaSorin does not publicly disclose ARIES installed-base counts, and the molecular dx franchise overall is not broken out separately from the broader IVD segment in DiaSorin annual reports [5]. COVID-19 reshaped this segment more than any other event in the past decade. Demand for respiratory molecular testing surged in 2020-2022, with hospital labs scrambling for cartridge supply across all platforms. DiaSorin's primary COVID play was the Simplexa COVID-19 Direct kit on the LIAISON MDX platform (high-throughput, lab-developed-test workflow) and a standalone ARIES SARS-CoV-2 EUA assay [9]. DiaSorin subsequently launched the ARIES Flu A/B & RSV+SARS-CoV-2 combination cartridge, but the public regulatory filings indicate the combination assay is CE-IVD marked for European use; there is no clear evidence of FDA clearance or EUA for the four-target ARIES combo in the US market [9]. That is a material competitive gap. Cepheid's Xpert Xpress CoV-2/Flu/RSV and BioFire's RP2.1 (now RP2.1plus) both offer FDA-cleared four-target cartridges at comparable price points, which is now the de facto target menu for winter respiratory testing. A flu/RSV-only cartridge is increasingly the wrong SKU for US hospital adoption decisions. Instrument economics for ARIES follow the standard lab-dx capital model: instrument placement (either direct purchase or reagent-rental contracts that amortize the instrument cost into per-test cartridge pricing) with cartridge pull-through as the recurring revenue. DiaSorin does not disclose ARIES instrument list price or per-system pull-through in financial filings; third-party GPO listings and reseller quotes for the ARIES system have historically been in the $40-60K range, with cartridges roughly $30-50 per test wholesale, but these are estimates rather than disclosed figures. Cepheid (within Danaher Diagnostics) provides the closest public benchmark on installed-base and reagent revenue disclosure for this segment. The 2021 DiaSorin acquisition rationale was less about ARIES and more about Luminex's xMAP bead-based multiplexing platform, which underpins large reference lab workflows. Expect ARIES to be maintained as a steady revenue line rather than a growth engine.

Clinically meaningful and commercially fine, but nothing changes the adoption curve from here. Multiplex respiratory PCR is settled standard of care in hospital labs; the question for any specific platform is whether it wins the next contract cycle, not whether the category exists. The biggest open question is whether DiaSorin gets a US-cleared four-target ARIES combo cartridge to market in time to defend the installed base against Cepheid Xpress CoV-2/Flu/RSV and BioFire RP2.1 - without it, hospital labs replacing instruments will increasingly default to platforms that already cover the full winter menu. Watchpoints: (1) DiaSorin's molecular dx segment commentary in quarterly results - if ARIES gets de-stressd or pulled into the LIAISON portfolio rebrand, that's a signal about long-term support [5]; (2) CMS CLFS updates to CPT 87631 reimbursement, which directly hits all players in this tier [8]; (3) FDA filings for an ARIES four-target combo - that's the binary event that determines whether ARIES stays competitive in the US. Data quality flag for our database: this node is tagged therapeutic_area = 'Bacterial Infections', which is wrong - influenza and RSV are viral. The MeSH normalization that happened on 2026-03-19 mapped 'Microbiology' to the wrong child term. Worth a backend fix. Re-check the commercial status in roughly 18 months or whenever DiaSorin issues a strategic update on the molecular dx franchise.